Loading…
Loading…
SDGR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for SDGR and 80,000+ other tickers.
See exactly how SDGR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SDGR and 80,000+ other tickers.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through…
Counterpoint Mutual Funds LLC purchased a new stake in shares of Schrodinger, Inc. (NASDAQ: SDGR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 40,894 shares of the company's stock, valued at approximately $1,270,000. Counterpoint Mutual Funds LLC owned about 0.06% of Schrodinger
NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in Nature that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center, the team discovered new insights that challenge long-held assumptions of the fundamental chemistry of lithium-ion batteries, including multi-lithium ion complexes that may.
Schrodinger (NASDAQ: SDGR - Get Free Report) and Claritev (NYSE: CTEV - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Profitability This table compares Schrodinger and Claritev's net margins, return
Teladoc Health (NYSE: TDOC - Get Free Report) and Schrodinger (NASDAQ: SDGR - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Risk and Volatility Teladoc Health has a beta of
On October 09, 2026, Schrodinger Inc (SDGR) shares rose 3.4%, currently trading at $27.28. This price is within a 52-week range of $10.95 to $33.78, demonstrati